Denali Therapeutics DEF 14A: Executive Compensation Details

Ticker: DNLI · Form: DEF 14A · Filed: Apr 17, 2025 · CIK: 1714899

Denali Therapeutics Inc. DEF 14A Filing Summary
FieldDetail
CompanyDenali Therapeutics Inc. (DNLI)
Form TypeDEF 14A
Filed DateApr 17, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: executive-compensation, proxy-statement, sec-filing

TL;DR

Denali Therapeutics dropped its 2024 exec comp filing. Check out the PEO pay details.

AI Summary

Denali Therapeutics Inc. filed its DEF 14A on April 17, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards and compensation for its principal executive officers (PEO).

Why It Matters

This filing provides transparency into how Denali Therapeutics compensates its top executives, which can influence investor perception and employee morale.

Risk Assessment

Risk Level: low — This is a routine annual filing disclosing executive compensation and does not inherently present new risks.

Key Players & Entities

  • Denali Therapeutics Inc. (company) — Filer of the DEF 14A
  • April 17, 2025 (date) — Filing date of the DEF 14A
  • December 31, 2024 (date) — Fiscal year end for compensation reporting

FAQ

What is the primary purpose of a DEF 14A filing?

A DEF 14A filing, also known as a Proxy Statement, is used to solicit shareholder votes and provide detailed information about matters to be voted on at an annual or special meeting of shareholders, including executive compensation.

When did Denali Therapeutics file its DEF 14A for the fiscal year ending December 31, 2024?

Denali Therapeutics filed its DEF 14A on April 17, 2025.

What specific type of information related to executives is typically found in a DEF 14A?

A DEF 14A typically includes details on executive compensation, including salary, bonuses, stock awards, option awards, and other benefits for the principal executive officers (PEO) and other named executive officers.

What does 'PEO' stand for in the context of this filing?

PEO stands for Principal Executive Officer, referring to the top executive officer(s) of the company.

What is the SIC code for Denali Therapeutics Inc. and what does it represent?

The SIC code for Denali Therapeutics Inc. is 2836, which represents Biological Products (No Diagnostic Substances).

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 17, 2025 regarding Denali Therapeutics Inc. (DNLI).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.